Cormedics
Cormedics Corporation is a medical device company focused on
developing novel technologies that selectively treat the entire
heart with drug, cell, gene, and device therapies by introduction
into the pericardial space.
Cormedics Corporation develops medical technologies that focus on putting more control into the hands of those who treat cardiac patients. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes. Cormedics is headquartered in Houston, Texas and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, pericardial effusion, and targeted cardiac drug delivery.
About Whole-Heart Therapeutics
Cormedics’ novel whole-heart therapies range from emergency access
to delivery of electrophysiology and echocardiography devices and
delivery of medications to the heart.
The company developed a
minimally-invasive instrument, the PeriPort™, that provides safe
access to the pericardial space surrounding the heart, to
deliver targeted treatment of heart disease.
Cormedics' intrapericardial products provide access to the
entire epicardial surface of the heart for pericardial effusion,
electrophysiology, and cardiac rhythm device therapies.
Intrapericardial drug delivery preferentially targets the heart and
coronary circulation with a minimum of systemic side effects. This
novel method of heart-specific therapeutics results in maximum
cardiac tissue drug levels and prolonged local drug retention times
at a fraction of the dosage. Cormedics has five issued U.S. patents
on intrapericardial therapies, including the PeriPort™. The
PeriPort™ is designed for intrapericardial delivery of cardiac rhythm
management devices, cardiotherapeutic drugs, and removal of
pericardial fluid (effusion).
Cormedics' Initial Product - PeriPort™
- A minimally invasive device to safely access the "normal" pericardial space.
- Allows drug therapies to be delivered to the coronary vasculature of the heart via the pericardial space.
- Permits fluid to be removed from or added into the pericardial space.
- Device and medication therapies can be delivered, and targeted to the entire heart.